Information Library
Results for: High-quality studies - Phase I/IIa - Phase II/III
To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.
- Sort by:
- Recently Added
- Title
-
Intarcia and Quintiles Finalize Innovative Alliance
Press Release — December 13, 2011 – To speed development of a potential ground-breaking therapy for Type 2 diabetes – Intarcia Therapeutics, Inc., and Quintiles announced the signing of definitive agreements making Quintiles a financial and strategic partner for the global clinical development of Intarcia’s ITCA 650 (DUROS® continuous subcutaneous delivery of exenatide).
-
Quintiles Launches China CRO, Kun Tuo
Press Release — December 13, 2011 – Further deepening its commitment to China, Quintiles announced the launch of Kun Tuo, a local contract research organization (CRO) built to service the unique needs of the Chinese biopharmaceutical industry and multinational biopharma companies operating in China.
-
Partnering is Key to Maximizing Rewards in Emerging Markets
Press Release — September 27, 2011 – While biopharmaceutical spending in emerging markets is growing at double-digit rates – much faster than in developed nations – opportunities in “pharmerging” countries must be balanced with accompanying costs and risks of entering new markets.
-
A Focus on CNS
Brochure — July 1, 2011
Quintiles is your ally for broad and deep CNS expertise in every aspect of the drug development process. -
The Molecular Biomarker Revolution in Non-Small Cell Lung Cancer
White Paper — June 23, 2011
In this new white paper Quintiles’ experts Christopher Ung, Jason Hill, Carrie Lee and Harish Dave review some of the most promising molecular pathways and targeted approaches for NSCLC, the critical role of diagnostics, and strategies to detect and address the emergence of resistance. -
Population PK/PD - Modeling and Simulation Optimization Tools
Brochure — February 11, 2011
Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation, available from Quintiles, is now endorsed by the FDA as often being instrumental in drug approval and labeling. -
Outsourcing Oncology Molecular Biomarkers - Considerations for Emerging Countries
Presentation — October 1, 2010
Download Christopher Ung of Quintiles recent presentation, Outsourcing Oncology Molecular Biomarkers - Considerations for Emerging Countries from the Clinical Development of Cancer Drugs in China -
Personalized Anti-Cancer Therapy Development in China
Presentation — October 1, 2010
Download the slides from Michael Shi, M.D. of Novartis recent presentation, Personalized Anti-Cancer Therapy Development in China from the Clinical Development of Cancer Drugs in China -
The New Health Clinical Brochure
Brochure — August 31, 2010
Japanese version available for download. -
Malaysia Prime Site
Video — July 2, 2010
Adam Chasse, Sr. Director, Access to Patients explains the importance of Prime Sites and the impact of our clinical research partnership with the University of Malaya Medical Centre in Malaysia.
